Voxzogo Generic Name & Formulations
Vosoritide 0.4mg, 0.56mg, 1.2mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains trehalose dihydrate, mannitol.
Human C type natriuretic peptide (CNP) analog.
Single-dose vials (2mL)—10 (w. prefilled diluent syringes, needles, syringes)
To increase linear growth in children with achondroplasia and open epiphyses.
Voxzogo Dosage and Administration
<5yrs: not established. Give by SC inj once daily (at same time each day) into middle of thighs, lower abdominal area, buttocks, or upper arms; rotate inj sites. Base dose on actual body weight. ≥5yrs (10–11kg): 0.24mg; (12–16kg): 0.28mg; (17–21kg): 0.32mg; (22–32kg): 0.4mg; (33–43kg): 0.5mg; (44–59kg): 0.6mg; (60–89kg): 0.7mg; (≥90kg): 0.8mg.
Voxzogo Boxed Warnings
Risk of transient decreases in BP. Ensure adequate food and fluid intake (~240–300mL) prior to initiation. Monitor body weight, growth, physical development regularly every 3–6 months. Permanently discontinue if no further growth potential due to closure of epiphyses. Renal impairment (eGFR <60mL/min/1.73m2): not recommended. Pregnancy. Nursing mothers.
Voxzogo Adverse Reactions
Inj site reactions (erythema, swelling, urticaria), vomiting, arthralgia, decreased BP, gastroenteritis, diarrhea, dizziness, ear pain, influenza.
Voxzogo Clinical Trials
Voxzogo Patient Counseling